Harrow Inc (OQ:HROW)

Mar 19, 2024 05:45 pm ET
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Company also posted its fourth quarter and year-end Letter to Stockholders and
Mar 05, 2024 07:00 am ET
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 19, 2024, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the “Investors” section of its website, harr
Feb 15, 2024 04:01 pm ET
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
Harrow, Inc. (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Apotex Inc. (“Apotex”), Canada’s largest pharmaceutical company, today jointly announced an exclusive out-licensing agreement under which Apotex will market and distribute VERKAZIA® and over-the-counter (OTC) Cationorm® PLUS in the Canadian market, and concurrently, pursue market approval in Canada for VEVYE®, IHEEZO®, and ZERVIATE®.
Jan 29, 2024 07:00 am ET
Harrow Announces New Appointments to its Board of Directors
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointments of Adrienne Graves, Ph.D., and Lauren Silvernail to the Company’s Board of Directors, effective immediately. Harrow’s Board now consists of six members.
Jan 11, 2024 07:00 am ET
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, twice-daily (BID) dosed prescription drug based on a “water‑free” semifluorinated alkane eyedrop technology, is now available in the U.S. – and includes a 100% Money‑Back Guarantee program. VEVYE, uniquely dispensed in a 10 microliter drop, is the first and only cyclosporine‑based product indicated for treating both the signs and symptoms of dry eye disease (DED).
Jan 03, 2024 07:15 am ET
Melt Pharmaceuticals Provides Corporate Update
Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today provided a corporate update. The Company previously announced that MELT-300 achieved the primary sedation endpoint in it
Jan 03, 2024 07:00 am ET
Harrow Partners with Leading Healthcare Market Access Technology Platforms
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it has partnered with three leading healthcare technology platforms to expand U.S. availability of VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, twice-daily (BID) dosed, ophthalmic solution prescription drug based on a “water-free” semifluorinated alkane (SFA) eyedrop technology. VEVYE, uniquely dispensed in a 10 microliter drop, is the first and only cyclosporine-based product indicated for treating both signs and symptoms of dry eye disease (DED).
Nov 29, 2023 07:00 am ET
Harrow Completes Transfer of the TRIESENCE® New Drug Application
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a synthetic corticosteroid indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids as well as visualization during vitrectomy. In January of 2023, Harrow
Nov 20, 2023 07:00 am ET
Harrow to Present at Two Investor Conferences in November
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the following two upcoming conferences:
Nov 15, 2023 12:03 pm ET
Investigation Into Harrow, Inc. (HROW) Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC is investigating whether Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW) complied with federal securities laws. On November 13, 2023, Harrow released its third quarter 2023 financial results revealing GAAP EPS and...
Nov 13, 2023 04:01 pm ET
Harrow Announces Third Quarter 2023 Financial Results
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the third quarter and nine months ended September 30, 2023. The Company also posted its third quarter Letter to Stockholders and
Oct 30, 2023 08:00 am ET
Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow
Oct 24, 2023 07:00 am ET
Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) for the following products:
Sep 29, 2023 08:00 am ET
Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced that effective today, it has changed its corporate name from “Harrow Health, Inc.” to “Harrow, Inc.” to align with the Company’s current five-year strategic plan, which includes an exclusive focus on eyecare pharmaceuticals.
Sep 26, 2023 08:00 am ET
Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation
Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced it recently entered into an exclusive development and license agreement with Catalent, the global leader in enabling the development and supply of better treatments across multiple modalities.
Aug 09, 2023 04:01 pm ET
Harrow Announces Second Quarter 2023 Financial Results
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the second quarter and six months ended June 30, 2023. The Company also posted its second quarter Letter to Stockholders and
Jul 31, 2023 07:00 am ET
Harrow Launches VIGAMOX® in the U.S.
Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. The U.S. commercial rights to VIGAMOX were
Jul 26, 2023 09:00 am ET
Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the second quarter ended June 30, 2023, on Wednesday, August 9, 2023, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow wi
Jul 19, 2023 07:00 am ET
Harrow Prices $60 Million Public Offering of Common Stock
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it priced an underwritten registered public offering of 3,380,282 shares of its common stock at a price of $17.75 per share for aggregate gross proceeds of $60 million. The offering is expected to close on or about July 21, 2023, subject to customary closing conditions. Harrow also announced that it had granted the underwriters a 30‑day option to purchase an additional 507,042 shares of its common stock in connection with the offering.
Jul 18, 2023 05:00 pm ET
Harrow Acquires Santen’s Branded Ophthalmic Portfolio
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliates of Santen Pharmaceutical Co., Ltd. (“Santen”) under which Harrow will acquire certain U.S. and Canadian commercial rights for the following branded products from Santen:
Jul 18, 2023 04:05 pm ET
Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the following select preliminary second quarter 2023 financial guidance:
Jul 18, 2023 04:04 pm ET
Harrow Announces Proposed Public Offering of Common Stock
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced a proposed underwritten registered public offering of its common stock, subject to market and certain other conditions. Harrow expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in connection with the offering.
Jul 18, 2023 04:01 pm ET
Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Novaliq GmbH, a German biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced an agreement under which Harrow will acquire the U.S. and Canadian commercial rights for VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, ophthalmic solution prescription drug based on Novaliq’s proprietary EyeSol® water-free technology. VEVYE, which is dispensed topically in a unique 10 microliter per one drop and is labeled for twice‑daily (BID) dosing, is the first and on
May 17, 2023 08:00 am ET
Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will participate in the upcoming B. Riley Securities 23rd Annual Institutional Investor Conference on Wednesday, May 24, 2023, at the Beverly Hilton Hotel in Beverly Hills, California.
May 16, 2023 11:45 am ET
Thinking about buying stock in Asure Software, Harrow Health, Sigma Lithium, Delta Air Lines, or Tingo?
NEW YORK, May 16, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ASUR, HROW, SGML, DAL, and TIO.
May 11, 2023 04:01 pm ET
Harrow Announces First Quarter 2023 Financial Results
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the first quarter ended March 31, 2023. The Company also posted its first quarter Letter to Stockholders and
May 04, 2023 08:00 am ET
Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the launch of FDA-approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting being held May 5‑8, 2023, in San Diego, California. The Harrow commercial team will be available to discuss IHEEZO and the entire Harrow portfolio of ophthalmi
May 02, 2023 07:00 am ET
Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S.
Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) for ILEVRO® (nepafenac ophthalmic suspension) 0.3%, NEVANAC® (nepafenac ophthalmic suspension) 0.1%, and MAXIDEX® (dexamethasone ophthalmic suspension) 0.1%. These three FDA-approved ophthalmic medicines, which are now commercially available under the Harrow umbrella, were among the five products that Harrow
Apr 27, 2023 08:00 am ET
Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2023, on Thursday, May 11, 2023, after the market close. The Company will also post its first quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will h
Apr 22, 2023 07:00 am ET
HARROW HEALTH INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Opt
NEW YORK, April 22, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc. ("Harrow Health" or the "Company") (NASDAQ: HROW).
Apr 15, 2023 07:00 am ET
HARROW HEALTH INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Opt
NEW YORK, April 15, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc.  ("Harrow Health" or the "Company") (NASDAQ: HROW).
Apr 08, 2023 07:00 am ET
HARROW HEALTH INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Opt
NEW YORK, April 8, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc. ("Harrow Health" or the "Company") (NASDAQ: HROW).
Apr 01, 2023 07:00 am ET
HARROW HEALTH SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Disc
NEW YORK, April 1, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc. ("Harrow Health" or the "Company") (NASDAQ: HROW).
Mar 28, 2023 02:59 pm ET
B. Riley Leads Financing to Support Harrow Health Acquisition
LOS ANGELES, March 28, 2023 /PRNewswire/ -- B. Riley Financial, Inc. (NASDAQ: RILY) ("B. Riley"), a diversified financial services platform, today announced that certain of its affiliates led the financing to support Harrow Health, Inc.'s ("Harrow") (Nasdaq: HROW) recent acquisition of the exclusive commercial rights to five FDA approved ophthalmic products. B. Riley provided $59.75 million in debt financing to Harrow in January 2023 upon consummation of the acquisition, and as part of a fully backstopped $125 million commitment. The B. Riley loan was repaid in full on March 27, 2023 in conn
Mar 28, 2023 07:00 am ET
Harrow Announces New $100 Million Secured Credit Facility with Oaktree
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it has entered into a $100 million secured credit financing agreement with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The interest-only secured credit facility carries an interest rate equal to the three-month secured overnight financing rate (SOFR) plus 6.50%, includes flexible terms and covenants, and is expected to mature in approximately three years. A portion of the proceeds from the new facility was used to pay off indebtedness under Harrow’s existing secured loan with an affili
Mar 25, 2023 07:00 am ET
HARROW HEALTH INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Opt
NEW YORK, March 25, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc.  ("Harrow Health" or the "Company") (NASDAQ: HROW).
Mar 23, 2023 04:06 pm ET
Harrow Announces Fourth Quarter and Year-End 2022 Financial Results
Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the fourth quarter and year ended December 31, 2022. The Company also posted its fourth quarter and year-end Letter to Stockholders and
Mar 19, 2023 04:10 pm ET
ROSEN, A LEADING AND RANKED FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation – HROW, HROWL, HROWM
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Harrow Health, Inc. (NASDAQ: HROW, HROWL, HROWM) resulting from allegations that Harrow may have issued...
Mar 18, 2023 07:00 am ET
HARROW HEALTH SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Disc
NEW YORK, March 18, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc. ("Harrow Health" or the "Company") (NASDAQ: HROW).
Mar 14, 2023 06:50 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation – HROW, HROWL, HROWM
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Harrow Health, Inc. (NASDAQ: HROW, HROWL, HROWM) resulting from allegations that Harrow may have issued...
Mar 13, 2023 06:20 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow Health, Inc. - HROW
NEW YORK, March 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow Health, Inc. ("Harrow" or the "Company") (NASDAQ: HROW). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Mar 13, 2023 07:00 am ET
Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved transitional pass-through reimbursement status for IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3%, which is indicated for ocular surface anesthesia.
Mar 11, 2023 10:00 am ET
HARROW HEALTH SHAREHOLDER ACTION REMINDER : Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Dis
NEW YORK, March 11, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc.  ("Harrow Health" or the "Company") (NASDAQ: HROW).
Mar 10, 2023 06:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow Health, Inc. - HROW
Pomerantz LLP is investigating claims on behalf of investors of Harrow Health, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Mar 06, 2023 12:02 pm ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation – HROW, HROWL, HROWM
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Harrow Health, Inc. (NASDAQ: HROW, HROWL, HROWM) resulting from allegations that Harrow may have issued...
Mar 06, 2023 08:00 am ET
Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance, responsible for overseeing and managing all regulatory related submissions and strategy related to the Company’s portfolio of new and existing products. Dr. Mannebach’s successful 30-year career in the pharmaceutical industry, much of which was focused in ophthalmology, includes leadership roles in regulatory affairs, quality assurance, program management and pharmaceutical product development.
Mar 02, 2023 08:00 am ET
Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2022, on Thursday, March 23, 2023, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the “Investors” section of its website, harrow.com
Mar 01, 2023 03:33 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow Health, Inc. - HROW
Pomerantz LLP is investigating claims on behalf of investors of Harrow Health, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Feb 28, 2023 04:39 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Harrow Health, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – HROW, HROWL, HROWM
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Harrow Health, Inc. (NASDAQ: HROW, HROWL, HROWM) resulting from allegations that Harrow may have issued...
Feb 27, 2023 07:18 pm ET
Harrow Health, Inc.: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises Harrow Health, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Harrow investors...
Feb 27, 2023 10:00 am ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Harrow Health, Inc. (“Harrow” or the “Company”) (NASDAQ:
Feb 25, 2023 09:00 am ET
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
BENSALEM, Pa., Feb. 25, 2023 /PRNewswire/ -- ­Law Offices of Howard G. Smith continues its investigation on behalf of Harrow Health, Inc. ("Harrow" or the "Company") (NASDAQ: HROW) investors concerning the Company's possible violations of federal securities laws.
Feb 25, 2023 06:00 am ET
HARROW HEALTH SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Disc
NEW YORK, Feb. 25, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Harrow Health, Inc. ("Harrow Health" or the "Company") (NASDAQ: HROW).
Feb 24, 2023 01:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Harrow Health, Inc. (“Harrow” or the “Company”) (NASDAQ:
Feb 24, 2023 10:00 am ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Harrow Health, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW) investors concerning the Company’s possible violations of federal securities laws.
Feb 23, 2023 08:41 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow Health, Inc. - HROW
NEW YORK, Feb. 23, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow Health, Inc. ("Harrow" or the "Company") (NASDAQ: HROW). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Feb 23, 2023 03:32 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Harrow Health, Inc. (“Harrow” or the “Company”) (NASDAQ:
Feb 23, 2023 08:45 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Harrow Health, Inc. (“Harrow” or “the Company”) (NASDAQ:
Feb 22, 2023 04:30 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Harrow Health, Inc. (“Harrow” or “the Company”) (NASDAQ:
Feb 22, 2023 03:16 pm ET
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation – HROW, HROWL, HROWM
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Harrow Health, Inc. (NASDAQ: HROW, HROWL, HROWM) resulting from allegations that Harrow may have issued materially misleading business information to the investing public.
Feb 22, 2023 01:27 pm ET
Harrow Health Shareholder News: Johnson Fistel Encourages Harrow Health Shareholders with Losses to Contact the Firm Regarding Class Action Investigation
Shareholder rights law firm Johnson Fistel, LLP is investigating whether Harrow Health, Inc. ("Harrow Health" or the "Company") (NASDAQ: HROW), any of its executive officers, or others violated securities laws by misrepresenting or failing to...
Feb 15, 2023 07:00 am ET
Harrow Launches Next-Generation Compounded Atropine Formulations
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the launch of its patent-pending, next-generation compounded Atropine formulations, which are now available through Harrow’s wholly owned compounding and mail order pharmacy subsidiary, ImprimisRx.
Feb 02, 2023 06:30 am ET
Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued a permanent, product-specific J-code for IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. Under the Healthcare Common Procedure Coding System (HCPCS), the IHEEZO
Jan 23, 2023 07:00 am ET
Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the closing of its previously announced acquisition of the exclusive U.S. commercial rights to five branded ophthalmic products: ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®.
Jan 05, 2023 07:00 am ET
Harrow Announces Availability of Fortisite™ Formulations for In-Office Use
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the availability, for in-office use, of Fortisite™ (compounded Tobramycin 1.5% + Vancomycin 5%) from its FDA‑registered and FDA‑inspected ImprimisRx® 503B outsourcing facility. Fortisite formulations are patent-pending high-concentration, refrigeration-stable, fortified antibiotic formulations, in solution. The availability of Fortisite for in-office use represents the first time eyecare professionals have been able to stock a fortified or high-concentration compounded antibiotic formulation for the im
Dec 21, 2022 09:21 am ET
Melt Pharmaceuticals’ MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study
Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced top-line results of its Phase 2 pivotal efficacy and safety study for its lead product candidate, MELT-300, a sublingual, needle- and opioid-free patented formulation for procedural sedation during cataract surgery. Based on the outcome of the MELT-300 data, the company intends to request a meeting with the U.S. Food and Drug Administration (FDA) to discuss the results of this study and the continued clinical development of MELT-300.
Dec 16, 2022 07:00 am ET
Harrow Secures Capital to Close Recently Announced Acquisition
Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, today announced the pricing of its underwritten registered public offering of $35 million aggregate principal amount of 11.875% senior notes due 2027 (the “Notes”). Harrow has granted the underwriters a 30‑day option to purchase an additional $5.25 million aggregate principal amount of Notes in connection with the offering. The offering is expected to close on December 20, 2022, subject to customary closi
Dec 14, 2022 06:32 am ET
Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and “BB” Rating from Egan-Jones
Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, today announced that it has commenced an underwritten registered public offering of $100 million aggregate principal amount of senior notes due 2027, subject to market and certain other conditions. Harrow expects to grant the underwriters a 30‑day option to purchase an additional 15% of the principal amount of senior notes sold in connection with the offering. The proposed offering is subject to market an
Dec 14, 2022 06:31 am ET
Harrow Prices $25 Million Offering
Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, today announced that it priced an underwritten registered offering of 2,376,426 shares of its common stock at a price of $10.52 per share for aggregate gross proceeds of $25 million. The offering is expected to close on or about December 16, 2022, subject to customary closing conditions.
Dec 14, 2022 06:30 am ET
Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced that it has entered into a binding agreement for the acquisition of the exclusive U.S. commercial rights to five FDA‑approved ophthalmic products from the Novartis group of companies (“Novartis”). This acquisition, when closed, will further expand and diversify Harrow’s portfolio of branded pharmaceutical products and its ability to serve the U.S. ophthalmic surgical and acute care markets. Subject to customary clo
Nov 30, 2022 08:00 am ET
Harrow and iOR Partners Expand National Product Supply Agreement
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, and iOR Partners, the pioneer in office-based surgery in the field of ophthalmology, today jointly announced the expansion of their national product supply agreement to provide Harrow’s entire formulary compounded ophthalmic products to iOR Partners’ expanding office-based surgery locations across the United States.
Nov 14, 2022 04:05 pm ET
Harrow Announces Third Quarter 2022 Financial Results
Harrow (NASDAQ: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced results for the third quarter ended September 30, 2022. The Company also posted its third quarter Letter to Stockholders and
Nov 10, 2022 08:00 am ET
Harrow Launches Atropine.com
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the launch of atropine.com, an easy-to-access ordering and marketing portal that is designed specifically for prescribers interested in compounded atropine formulations. All atr
Oct 28, 2022 08:00 am ET
Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced that it will release its financial results for the third quarter ended September 30, 2022, on Monday, November 14, 2022, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” section of its website,
Oct 27, 2022 08:00 am ET
Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300
Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation and analgesia, today announced the dosing of the last patient in its Phase 2 pivotal efficacy and safety study for its lead product candidate, MELT-300, a sublingual, needle- and opioid-free patented formulation for procedural sedation and analgesia during cataract surgery. Top-line results from this study are expected before the end of the year.
Oct 05, 2022 05:35 pm ET
Harrow Sells Non-Ophthalmic Compounding Business
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the sale of its non‑ophthalmic compounding business to Innovation Compounding Pharmacy, LLC, an affiliate of Revelation Pharma Corporation (“Revelation”).
Sep 29, 2022 07:00 am ET
ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation
ImprimisRx, America’s #1 Ophthalmic Pharmacy™, today announced the availability of Fortisite™, which includes a patent-pending compounded combination of Tobramycin 1.5% and Vancomycin 5%.
Sep 27, 2022 01:50 pm ET
Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, and Sintetica, S.A., a growing pharmaceutical company focused on analgesics, local anesthetics, and sterile injectable solutions, today jointly announced the U.S. Food and Drug Administration (FDA) approval of IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. IHEEZO is a sterile, single-patient‑use, physician‑administered, ophthalmic gel preparation, containing no preservatives, that is safe a
Aug 11, 2022 08:00 am ET
Harrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medicines, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference to be held on August 17, 2022.
Aug 09, 2022 04:01 pm ET
Harrow Health Announces Second Quarter 2022 Financial Results
Harrow Health, Inc. (NASDAQ: HROW), an eyecare pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medicines, today announced results for the second quarter ended June 30, 2022. The Company also posted its second quarter Letter to Stockholders and
Jul 27, 2022 07:00 am ET
Harrow Health to Announce Second Quarter 2022 Financial Results on August 9, 2022
Harrow Health, Inc. (Nasdaq: HROW), an eye health pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medications that are accessible and affordable, today announced that it will release its financial results for the second quarter ended June 30, 2022, on Tuesday, August 9, 2022, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors” section of its website,
Jun 24, 2022 08:00 am ET
Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) of recently acquired, FDA-approved ophthalmic medicines, IOPIDINE® 1%, MAXITROL® 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5%. Harrow also announced that IOPIDINE 1% and MAXITROL are now commercially available; Harrow intends to commercialize MOXEZA 0.5% at a later date. Harrow purchased these medicines in December 2021 and has been receiving net profits from unit sales during the NDA transfer process.
May 05, 2022 04:01 pm ET
Harrow Health Announces First Quarter 2022 Financial Results
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced results for the first quarter ended March 31, 2022. The Company also posted its first quarter Letter to Stockholders and
May 04, 2022 08:00 am ET
Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation
Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation and analgesia, today announced top-line results of its phase 1 pharmacokinetics (PK) study of MELT-210. MELT-210 is a fixed dose of 3 mg of midazolam formulated in a proprietary rapidly dissolving sublingual tablet technology for procedural sedation.
Apr 22, 2022 08:00 am ET
Harrow Health to Participate in B. Riley Securities’ Annual Neuro & Ophthalmology Investor Conference
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the B. Riley Securities’ Annual Neuro & Ophthalmology Investor Conference, which will be held virtually on Wednesday, April 27, 2022, at 2:00 p.m. ET/1:00 p.m. CT.
Apr 20, 2022 07:00 am ET
Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the first quarter ended March 31, 2022, on Thursday, May 5, 2022, after the market close. The Company will also post its first quarter Letter to Stockholders to the “Investors” section of its website, harrowinc.com
Mar 31, 2022 07:00 am ET
Harrow Health Announces Appointments to Its Board of Directors
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced the appointments of Perry J. Sternberg and Marty Makary, M.D., M.P.H. to the Company’s Board of Directors, effective immediately. The Company also announced that Robert J. Kammer has resigned from Harrow Health’s Board of Directors, effective immediately. With these changes, Harrow Health’s Board will consist of six members.
Mar 10, 2022 04:01 pm ET
Harrow Health Announces Fourth Quarter and Year-End 2021 Financial Results
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced results for the fourth quarter and year ended December 31, 2021. The Company also posted its fourth quarter Letter to Stockholders and
Mar 10, 2022 08:00 am ET
Melt Pharmaceuticals Names Experienced Executive Brad Osborne as Chief Financial Officer
Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first‑in‑class medicines for sedation and analgesia, today announced the addition of Brad Osborne as Chief Financial Officer. Osborne brings 20 years of extensive finance and accounting experience.
Feb 24, 2022 08:00 am ET
Harrow Health to Announce Fourth Quarter and Year-End 2021 Financial Results on March 10, 2022
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2021, on Thursday, March 10, 2022, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the “Investors” section of its website,
Feb 22, 2022 07:00 am ET
Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) filing for AMP-100, the Company’s drug candidate for ocular surface anesthesia and intraoperative pain management during ocular surgery. The FDA has assigned the application standard review and a Prescription Drug User Fee Act (PDUFA) target action date of October 16, 2022.
Feb 15, 2022 07:00 am ET
Harrow Health to Present at Aegis Virtual Conference
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will present a company overview at the Aegis Capital Corp. Virtual Conference to be held on February 23-25, 2022.
Feb 08, 2022 08:00 am ET
Harrow Health Publishes Corporate Transparency Report
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that its inaugural 2022 Corporate Transparency Report is now available under the Investors section of the Company’s website, harrowinc.com. The report focuses on Harrow Health’s commitment to initiatives that it believes support its mission to make innovative,
Jan 10, 2022 06:45 am ET
Harrow Health to Participate in H.C. Wainwright BioConnect Conference
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the H.C. Wainwright BioConnect Conference to be held virtually on January 10-13, 2022.
Jan 04, 2022 08:00 am ET
Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA
Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first‑in‑class medicines for sedation and analgesia, today announced the filing of two investigational new drug applications (INDs) with the U.S. Food and Drug Administration (FDA) for two sublingual, IV-free, non‑opioid formulations – MELT-210 (midazolam) for procedural sedation and MELT-400 (ketamine) for pain. Both formulations have been developed in an exclusive partnership with Catalent (NYSE: CTLT) using its proprietary Zydis® orally disintegrating tablet (ODT) technology, which is currently used in 35 product
Dec 20, 2021 07:00 am ET
Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced its acquisition of the exclusive U.S. commercialization rights of four FDA-approved ophthalmic medicines, IOPIDINE® 1% and 0.5% (apraclonidine hydrochloride), and MAXITROL® (neomycin and polymyxin B sulfate and dexamethasone) 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5% (moxifloxacin hydrochloride), from Novartis. The acquired products, which will be sold, marketed, and distributed through Harrow’s wholly owned subsidiary, ImprimisRx, combined with the Company’s existing ophthalmic‑focused product portfo
Dec 13, 2021 08:00 am ET
Harrow Health Added to the Nasdaq Biotechnology Index
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.
Dec 07, 2021 04:31 pm ET
EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU®
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, and ImprimisRx, one of the nation’s leading...
Nov 09, 2021 04:01 pm ET
Harrow Health Announces Third Quarter 2021 Financial Results
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced results for the third quarter and nine months ended September 30, 2021. The Company also posted its third quarter Letter to Stockholders and
Oct 25, 2021 09:00 am ET
Harrow Health to Announce Third Quarter 2021 Financial Results on November 9, 2021
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the third quarter and nine months ended September 30, 2021, on Tuesday, November 9, 2021, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” section of its website,
Sep 02, 2021 08:00 am ET
Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, and Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first-in-class medicines for sedation and analgesia, today announced that Harrow Health has provided a $13.5 million senior secured loan to Melt Pharmaceuticals.
Aug 18, 2021 07:00 am ET
Harrow Health Acquires Ophthalmic Surgical Drug Candidate From Wakamoto Pharmaceutical Co., Ltd.
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian commercial rights for drug candidate MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection.
Aug 12, 2021 07:45 am ET
Harrow Health to Participate in Two Upcoming Virtual Investor Conferences
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in two upcoming virtual investor conferences.
Aug 10, 2021 04:01 pm ET
Harrow Health Announces Second Quarter 2021 Financial Results
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced record results for the second quarter and first half ended June 30, 2021. The Company also posted its second quarter Letter to Stockholders and
Jul 27, 2021 07:00 am ET
Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Sintetica, S.A., a growing pharmaceutical company focused on analgesics, local anesthetics and sterile injectable solutions, to acquire the marketing and supply rights in the U.S. and Canada for AMP-100, a patented ophthalmic surgical drug candidate. When approved, AMP-100 will provide ocular surface anesthesia during ophthalmic interventions such as cataract surgery and intravitreal injections, which are estimated to total over 10 million procedures annually
Jul 26, 2021 09:00 am ET
Harrow Health to Announce Second Quarter 2021 Financial Results on August 10, 2021
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the second quarter and six months ended June 30, 2021, on Tuesday, August 10, 2021, after the market close....
Jul 19, 2021 08:00 am ET
NovaBay Pharmaceuticals Partners with Harrow Health’s ImprimisRx® to Promote Prescription Avenova
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces it has partnered with ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical businesses, to promote prescription Avenova. ImprimisRx, a wholly ow
Jul 15, 2021 08:00 am ET
Harrow Health Granted Two Patents for Novel Surgical Dilation Formulation
Harrow Health, Inc. (NASDAQ: HROW) an ophthalmic-focused healthcare company, today announced that the United States Patent and Trademark Office issued two Patents, No. US 10,993,921, B2, dated May 4, 2021, and No. US 11,045,432 B2, dated June 29,...
Jun 17, 2021 04:01 pm ET
Harrow Health Announces Closing of $20 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026
Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the closing of its underwritten registered public offering of $20 million aggregate principal amount of 8.625% senior...
Jun 14, 2021 05:59 pm ET
Harrow Health Announces Pricing of $17.5 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026
Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the pricing of its underwritten registered public offering of $17.5 million aggregate principal amount of 8.625% senior...
Jun 14, 2021 07:45 am ET
Harrow Health Announces Offering of $17.5 Million of 8.625% Senior Notes Due 2026 and “BB” Rating from Egan-Jones
Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced that it has commenced an underwritten registered public offering of $17.5 million aggregate principal amount of its...
Jun 03, 2021 08:15 am ET
Visionology Acquires Exclusive Worldwide License to SPARCS Contrast Sensitivity Testing Technology
Visionology, a subsidiary of Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced that it had acquired a worldwide exclusive license from Spaeth/Richman Contrast Sensitivity Center (SPARCS) to make its...
Jun 01, 2021 09:00 am ET
Harrow Health Launches New Corporate and Investor Website
Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the launch of its newly redesigned corporate and investor website, harrowinc.com. The new website, which is...
May 17, 2021 09:00 am ET
Leading Peer-Reviewed Ophthalmic Journal Publishes Study on ImprimisRx’s Proprietary Klarity-C® Drops
ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business and a wholly owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced that a study of its Klarity-C Drops®...
May 11, 2021 04:01 pm ET
Harrow Health Announces Record First Quarter 2021 Financial Results
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced record results for the first quarter ended March 31, 2021. The Company also posted its first quarter Letter to Stockholders to the “Investors” section of...
May 05, 2021 04:03 pm ET
Harrow Health Raises Approximately $11 Million in Sale of Series B Preferred Stock
Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced that the Company has closed on a private sale to B. Riley Securities, Inc. of 440,000 shares of its newly created...
May 05, 2021 04:01 pm ET
Harrow Health Announces Full Exercise and Closing of Option to Purchase Additional Senior Notes
Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the closing of an additional $5.0 million of 8.625% senior notes due 2026 (the “Additional Notes”), pursuant to the...
Apr 27, 2021 09:00 am ET
Harrow Health to Announce First Quarter 2021 Financial Results on May 11, 2021
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the first quarter ended March 31, 2021, on Tuesday, May 11, 2021, after the market close. The Company will...
Apr 20, 2021 04:01 pm ET
Harrow Health Announces Closing of $50 Million Offering of Senior Notes Due 2026
Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the closing of its underwritten registered public offering of $50 million aggregate principal amount of 8.625% senior...
Apr 15, 2021 05:00 pm ET
Harrow Health Announces Pricing of $50 Million Offering of Senior Notes Due 2026
Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the pricing of its underwritten registered public offering of $50 million aggregate principal amount of 8.625% senior...
Apr 14, 2021 04:01 pm ET
Harrow Health Announces Offering of $25 Million Senior Notes Due 2026 and “BB” Rating from Egan-Jones
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced it has commenced an underwritten registered public offering of $25 million aggregate principal amount of senior notes due 2026 (the “Notes”), subject to...
Apr 14, 2021 04:00 pm ET
Harrow Health Announces Preliminary First Quarter 2021 Financial Results
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced certain preliminary unaudited financial results for the first quarter ended March 31, 2021. Preliminary Estimate of Results for the Three Months Ended...
Mar 08, 2021 04:01 pm ET
Harrow Health Announces Fourth Quarter and Year-End 2020 Financial Results
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced results for the fourth quarter and year ended December 31, 2020. The Company also posted its fourth quarter Letter to Stockholders to the “Investors”...
Mar 02, 2021 09:00 am ET
Harrow Health to Participate in H.C. Wainwright Global Life Sciences Conference
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the H.C. Wainwright Global Life Sciences Conference...
Feb 25, 2021 09:00 am ET
Harrow Health to Announce Fourth Quarter and Year-End 2020 Financial Results on March 8, 2021
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2020, on Monday, March 8, 2021, after the Nasdaq market...
Feb 09, 2021 07:00 am ET
Melt Pharmaceuticals Completes Phase 1 Study for Sublingual, Non-Opioid Pain and Sedation Drug Candidate
Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first-in-class medicines for sedation and analgesia, announced results from its MELT Phase 1 study, a comparative bioavailability study with the objective of...
Dec 03, 2020 07:30 am ET
Study on Patented Non-Opioid MKO Melt® Reported in Leading Peer-Reviewed Anesthesia Journal
Harrow Health, Inc. (NASDAQ: HROW) today announced that a study featuring its patented MKO Melt® formulation has been published in the American Association of Nurse Anesthetists (AANA) Journal. Each sublingually administered MKO Melt troche...
Nov 20, 2020 07:30 am ET
Harrow Health Announces Participation at the Piper Sandler 32nd Annual Healthcare Conference
Harrow Health, Inc. (NASDAQ: HROW) today announced that Mark Baum, Harrow’s Chief Executive Officer, and Andrew Boll, Harrow’s Chief Financial Officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place...
Nov 09, 2020 04:01 pm ET
Harrow Health Publishes Third Quarter 2020 Letter to Stockholders
Harrow Health, Inc. (NASDAQ: HROW) today reported results for the third quarter 2020. Please click here to review Harrow Health’s Letter to Stockholders for the third quarter 2020. Mark L. Baum, CEO of Harrow Health, commented, “The third quarter...
Oct 27, 2020 07:30 am ET
Harrow Health to Announce Third Quarter 2020 Financial Results on November 9, 2020
Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, November 9, 2020, it will release third quarter 2020 financial results and host a conference call at 4:45 p.m. Eastern Standard Time / 1:45 p.m. Pacific...
Sep 30, 2020 08:00 am ET
Harrow Health Appoints Larry Van Horn to its Board of Directors
Harrow Health, Inc. (NASDAQ: HROW) today announced the appointment of Larry Van Horn to its Board of Directors. Mark L. Baum, CEO of Harrow Health, commented, “I am honored to welcome Larry to the Harrow Health Board of Directors where his work on...
Sep 11, 2020 11:22 am ET
Harrow Health to Attend Lake Street’s Virtual 4th Annual (BIG4) Conference September 17, 2020
Harrow Health, Inc. (NASDAQ: HROW) today announced that it will be attending Lake Street’s 4th Annual Best Ideas Growth (BIG4) Conference September 17, 2020, on a virtual platform. Mark L. Baum, CEO, and Andrew Boll, CFO, will be available...
Aug 10, 2020 04:00 pm ET
Harrow Health Publishes Second Quarter 2020 Letter to Stockholders
Harrow Health, Inc. (NASDAQ: HROW) today reported results for the second quarter 2020.  Please click here to review Harrow Health’s Letter to Stockholders for the second quarter 2020. Mark L. Baum, CEO of Harrow Health, commented, “Our team made...
Aug 04, 2020 07:00 am ET
EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce U.S. Commercial Alliance for DEXYCU®
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, and ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical...
Jul 27, 2020 07:30 am ET
Harrow Health to Announce Second Quarter 2020 Financial Results on August 10, 2020
Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, August 10, 2020, it will release second quarter 2020 financial results and host a conference call at 5:00 p.m. Eastern Daylight Time / 2:00 p.m. Pacific...
Jul 13, 2020 07:30 am ET
Leading Peer-Reviewed Journal Publishes Clinical Study on ImprimisRx’s Combination Prescription Eyedrops
ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), is pleased to announce the findings from a randomized contralateral...
Jun 29, 2020 07:30 am ET
Harrow Health Set to Join Russell 2000® Index and Russell 3000® Index
Harrow Health, Inc. (NASDAQ: HROW) today announced that it is set to join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market...
Jun 18, 2020 07:30 am ET
ImprimisRx’s Patented Klarity-C® 0.1% Cyclosporine Preservative-Free Formulation May Now Be Prescribed By Florida’s 2,000 Optometrists
ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its Klarity-C preservative-free formulation (0.1%...
May 11, 2020 04:01 pm ET
Harrow Health Publishes First Quarter 2020 Letter to Stockholders
Harrow Health, Inc. (NASDAQ: HROW) today reported results for the first quarter 2020.  Please click here to review Harrow Health’s Letter to Stockholders for the first quarter 2020. Mark L. Baum, CEO of Harrow Health, commented, “As we are...
Apr 27, 2020 07:30 am ET
Harrow Health to Announce First Quarter 2020 Financial Results on May 11, 2020
Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, May 11, 2020, it will release first quarter 2020 financial results and host a conference call at 5:00 p.m. Eastern Daylight Time / 2:00 p.m. Pacific...
Mar 24, 2020 07:30 am ET
ImprimisRx® Announces Exclusive Agreement with Doxy.me to Provide Healthcare Professionals with Telemedicine Services
Harrow Health, Inc. (NASDAQ: HROW) and ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow, announced that they have entered into an exclusive...
Mar 17, 2020 07:30 am ET
Harrow Health Appoints Teresa Sparks to its Board of Directors
Harrow Health, Inc. (NASDAQ: HROW) today announced the appointment of Teresa Sparks to its Board of Directors. Mark L. Baum, CEO of Harrow Health, commented, “I am honored to welcome Teresa to the Harrow Health Board of Directors.  Her extensive...
Mar 13, 2020 07:31 am ET
Harrow Health Publishes Fourth Quarter 2019 Letter to Stockholders
Harrow Health, Inc. (NASDAQ: HROW) today reported results for the fourth quarter 2019.  Please click here to review Harrow Health’s Letter to Stockholders for the fourth quarter 2019. Mark L. Baum, CEO of Harrow Health, commented, “During 2019, we...
Mar 12, 2020 07:30 am ET
ImprimisRx® Announces Supply Agreement with EyeCare Services Partners
ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, and a wholly-owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), announced that it has agreed to a product supply agreement with...
Mar 09, 2020 07:30 am ET
ImprimisRx® Announces Supply Agreement with iOR Partners
ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, and a wholly-owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), announced that it has agreed to a product supply agreement with...
Mar 03, 2020 07:30 am ET
ImprimisRx® Announces Supply Agreement with Vision Center Network of America (VCNA)
ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, and a wholly-owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), announced that it has agreed to a product supply agreement with...
Feb 27, 2020 07:30 am ET
Harrow Health to Announce Fourth Quarter 2019 Financial Results on March 13, 2020
Harrow Health, Inc. (NASDAQ: HROW) today announced that before the open of trading on Friday, March 13, 2020, it will release fourth quarter 2019 financial results and host a conference call at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific...
Dec 10, 2019 07:30 am ET
ImprimisRx’s FDA-Registered Outsourcing Facility Issued California License
ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), announced that on December 9, 2019, its FDA-registered 503B...
Nov 13, 2019 04:03 pm ET
Harrow Health Publishes Third Quarter Letter to Stockholders
Harrow Health, Inc. (NASDAQ: HROW) today reported results for the third quarter 2019.  Please click here to review Harrow Health’s complementary Letter to Stockholders for the third quarter 2019. Mark L. Baum, CEO of Harrow Health, commented,...
Oct 24, 2019 07:30 am ET
Harrow Health to Announce Third Quarter 2019 Financial Results on November 13, 2019
Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Wednesday, November 13, 2019, it will release third quarter 2019 financial results and host a conference call at 5:00 p.m. Eastern Standard Time / 2:00 p.m....
Oct 23, 2019 07:30 am ET
Solas BioVentures Co-Founder David Adair, M.D. Joins Mayfield Pharmaceuticals Board of Directors
Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced David Adair, M.D. will join the Mayfield Pharmaceuticals Board of Directors. Dr. Adair is a Co-Founder and Managing Director of...
Oct 08, 2019 07:35 am ET
Mayfield Pharmaceuticals to Present at the SVB Leerink New Treatments Focused on Women’s Health Conference on October 10, 2019
Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its Chief Executive Officer, Melissa Bradford-Klug, will discuss Mayfield’s advancements in developing new anti-infective...
Oct 08, 2019 07:30 am ET
ImprimisRx to Focus on Investments in Quality at the 2019 American Academy of Ophthalmology Meeting
ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its participation at the upcoming 2019 American...
Aug 27, 2019 07:30 am ET
Harrow Health to Attend Lake Street’s 3rd Annual Best Ideas Growth Conference September 12, 2019
Harrow Health, Inc. (NASDAQ: HROW) today announced that it will be attending Lake Street’s 3rd Annual BIG Conference September 12, 2019. Mark L. Baum, CEO, and Andrew Boll, CFO, will be available for one-on-one meetings with investors to provide...
Aug 15, 2019 04:22 pm ET
SHAREHOLDER ALERT: Investigation of Harrow Health Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC is investigating whether certain statements made by Harrow Health, Inc. (“Harrow Health” or the “Company”) (NASDAQ: HROW) complied with federal securities laws. On August 14, 2019, Harrow Health filed a form 10-Q with the SEC that disclosed its Park facility in California is required to surrender its California pharmacy license by August 27. The price of Harrow Health stock fell following the announcement.
Aug 14, 2019 04:01 pm ET
Harrow Health Announces Second Quarter 2019 Results
Harrow Health, Inc. (NASDAQ: HROW) today reported results for the second quarter 2019. Second Quarter 2019 and Other Recent Notable Highlights: 46% year-over-year increase in ImprimisRx ophthalmology gross revenue to $12.1 millionPharmaceutical...
Aug 02, 2019 07:30 am ET
Harrow Health Forms Stowe Pharmaceuticals Subsidiary to Develop Broad Spectrum Anti-Microbial Ophthalmic and Otic Therapeutics
Harrow Health, Inc. (NASDAQ: HROW) today announced that its newly formed subsidiary, Stowe Pharmaceuticals, Inc., has entered into an agreement with TGV Health to acquire worldwide rights to the Zian™ anti-microbial molecule for ophthalmic and otic...
Jul 31, 2019 07:30 am ET
Harrow Health Announces Launch of Mayfield Pharmaceuticals
Harrow Health, Inc. (NASDAQ: HROW), today announced it has filed a Form 8-K with the Securities and Exchange Commission containing a corporate presentation for its subsidiary, Mayfield Pharmaceuticals, Inc.  Mayfield is focused on making a...
Jul 25, 2019 07:30 am ET
Harrow Health to Announce Second Quarter 2019 Financial Results on August 14, 2019
Harrow Health, Inc. (NASDAQ: HROW) today announced it will release second quarter 2019 financial results after the close of trading on Wednesday, August 14, 2019.  The company will host a conference call at 4:30 p.m. Eastern Daylight Time / 1:30...
Jun 25, 2019 07:30 am ET
Harrow Health Adds Two Senior Executives to its Nashville Team
Harrow Health, Inc. (NASDAQ: HROW) today announced that it has promoted Dennis Saadeh, PharmD as its Chief of Formulation Strategy and has hired Larry Dillaha, MD as its Chief Medical Officer.  Dr. Saadeh, who is a 30-year veteran of pharmaceutical...
Jun 18, 2019 10:51 am ET
Harrow Health, Inc to Locate Headquarters in Nashville, Tennessee
Tennessee Governor, Bill Lee, Department of Economic and Community Development Commissioner Bob Rolfe and Harrow Health, Inc (NASDAQ: HROW) announced today that the company will locate its headquarters operations in Nashville. Harrow Health plans...
May 29, 2019 07:00 am ET
Harrow Health Announces Renegotiated Debt Facility with SWK Holdings
Harrow Health, Inc. (NASDAQ: HROW) today announced it has amended its loan agreement with SWK Funding LLC and its partners.  SWK Funding LLC is a subsidiary of SWK Holdings Corporation, a healthcare-focused investment firm. Under the amended...
May 09, 2019 04:01 pm ET
Harrow Health Announces First Quarter 2019 Financial Results
Harrow Health, Inc. (NASDAQ: HROW) today reported results for the first quarter 2019. First Quarter 2019 and Other Recent Notable Highlights: Consolidated revenue increased 39% year-over-year to a new record of $12.3 millionImprimisRx...
May 07, 2019 07:00 am ET
Harrow Health to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019
Harrow Health, Inc. (NASDAQ: HROW) today announced that its Chief Executive Officer, Mark L. Baum, will present an update on the company’s business at the 20th Annual B. Riley FBR Institutional Investor Conference on Wednesday, May 22nd, 2019 at...
May 02, 2019 07:00 am ET
Harrow Health to Announce First Quarter 2019 Financial Results on May 9, 2019
Harrow Health, Inc. (NASDAQ: HROW) today announced it will release first quarter 2019 financial results after the close of trading on Thursday, May 9, 2019.  The company will host a conference call at 4:30 p.m. Eastern Daylight Time / 1:30 p.m....
Apr 30, 2019 07:00 am ET
ImprimisRx to Introduce New Formulations at Cataract & Refractive Surgery Annual Meeting
ImprimisRx, the ophthalmology-focused pharmaceutical compounding subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its participation at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held at the...
Mar 12, 2019 04:01 pm ET
Harrow Health Announces Fourth Quarter 2018 Financial Results
Harrow Health, Inc. (NASDAQ: HROW) today reported results for the fourth quarter 2018. Fourth Quarter 2018 and Other Recent Notable Highlights: Revenues increased 55% year-over-year to a new record of $11.4 millionGross Ophthalmology revenue...
Mar 04, 2019 07:00 am ET
Harrow Health to Attend 31st Annual ROTH Conference on March 18, 2019
Harrow Health, Inc. (NASDAQ: HROW) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019 at The Ritz Carlton, Laguna Niguel in Dana Point, CA.  Mark L. Baum, the company’s Chief Executive Officer, and Andrew R....
Feb 28, 2019 07:00 am ET
Harrow Health to Announce Fourth Quarter 2018 Financial Results on March 12, 2019
Harrow Health, Inc. (NASDAQ: HROW) today announced it will release fourth quarter 2018 financial results after the close of trading on Tuesday, March 12, 2019.  The company will host a conference call at 4:30 p.m. Eastern Daylight Time / 1:30 p.m....
Feb 13, 2019 07:00 am ET
Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulations
Melt Pharmaceuticals, Inc., a specialty pharmaceutical company recently deconsolidated from Harrow Health, Inc. (NASDAQ: HROW), today announced the U.S. Patent and Trademark office has issued two additional patents covering the company’s innovative...
Feb 07, 2019 07:00 am ET
Harrow Health Subsidiary, Mayfield Pharmaceuticals, Inc., Acquires Patented Dyspareunia Drug Candidate and Other Intellectual Property
Harrow Health, Inc. (NASDAQ: HROW), today announced that its subsidiary, Mayfield Pharmaceuticals, Inc., has acquired drug formulation assets and intellectual property, including three recently issued patents, from Elle Pharmaceutical, LLC, for...
Feb 05, 2019 07:00 am ET
Harrow Health Announces $11 Million Series A Financing for Melt Pharmaceuticals Subsidiary
Melt Pharmaceuticals, Inc., an affiliated company of Harrow Health, Inc. (NASDAQ: HROW), today announced it has entered into definitive stock purchase agreements with accredited and institutional investors to raise proceeds of approximately $11...
Dec 31, 2018 07:00 am ET
Imprimis Pharmaceuticals, Inc. Completes Name Change to Harrow Health, Inc.
Harrow Health, Inc. (formerly known as Imprimis Pharmaceuticals, Inc.) (NASDAQ: IMMY) announced it has formally changed its name and that it will trade as “HROW” on The NASDAQ Capital Markets beginning at market open January 2, 2019.  Mark L....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.